Adults 18 to 65, any sex, with Spinal Cord Injuries or Metabolic Syndrome. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Percent Body Fat Assessed by DXA at Baseline and 21 WeeksPrimary· Baseline, 21 weeks
Percent body fat will be assessed in percentage using Dual Energy x-ray absorbency (DXA). Assessments will be conducted at baseline and at 21 weeks to evaluate changes in body composition over time.
Baseline
Group
Value
95% CI
Exercise and Diet
26.6
± 9.0
Diet Only
25.9
± 9.6
21 weeks
Group
Value
95% CI
Exercise and Diet
22.0
± 5.3
Diet Only
25.6
± 6.9
Fat Free MassPrimary· Baseline, 21 weeks
Body composition will be assessed using Dual-Energy X-ray Absorptiometry (DXA), which provides precise measurements of both absolute fat mass (FM) and absolute fat-free mass (FFM) in kilograms. FFM represents a distinct component of total body mass and will be used to evaluate lean tissue (i.e.,FFM) over time.
Baseline
Group
Value
95% CI
Home-Based Exercise & Diet Group
48.7
± 8.3
Home-Based Diet Alone Group
48.1
± 6.8
21 weeks
Group
Value
95% CI
Home-Based Exercise & Diet Group
48.5
± 7.1
Home-Based Diet Alone Group
49.4
± 7.7
Change in Insulin Sensitivity (Si)Primary· Baseline, 21 weeks
Insulin Sensitivity will be measured using intravenous glucose tolerance test (IVGTT)
Baseline
Group
Value
95% CI
Home-Based Exercise & Diet Group
4.1
± 9.9
Home-Based Diet Alone Group
3.2
± 4.3
21 weeks
Group
Value
95% CI
Home-Based Exercise & Diet Group
1.8
± 1.5
Home-Based Diet Alone Group
1.5
± 1.4
Change in Glucose Effectiveness (Sg)Primary· Baseline, 21 weeks
Glucose Effectiveness will be measured using IVGTT
Baseline
Group
Value
95% CI
Home-Based Exercise & Diet Group
0.027
± 0.016
Home-Based Diet Alone Group
0.019
± 0.018
21 weeks
Group
Value
95% CI
Home-Based Exercise & Diet Group
0.027
± 0.008
Home-Based Diet Alone Group
0.015
± 0.006
Change in Basal Metabolic Rate (BMR)Primary· Baseline, 21 weeks
BMR will be measured by indirect calorimetry
Baseline
Group
Value
95% CI
Home-Based Exercise & Diet Group
1587.4
± 249.5
Home-Based Diet Alone Group
1502.5
± 234.6
21 weeks
Group
Value
95% CI
Home-Based Exercise & Diet Group
1588.8
± 139.8
Home-Based Diet Alone Group
1510.0
± 178.4
High Density Lipoprotein Cholesterol (HDL-C)Secondary· Baseline, 21 weeks
HDL-C will be measured from blood serum samples
Baseline
Group
Value
95% CI
Home-Based Exercise & Diet Group
40.4
± 8.0
Home-Based Diet Alone Group
41.5
± 12.4
21 weeks
Group
Value
95% CI
Home-Based Exercise & Diet Group
41.8
± 7.4
Home-Based Diet Alone Group
39.7
± 10.3
Change in Total Cholesterol : HDL-C RatioSecondary· Baseline, 21 weeks
Total Cholesterol HDL-C ratio will be calculated from blood serum samples reported as a numeric value, representing the ratio of Total Cholesterol to HDL-C.
Baseline
Group
Value
95% CI
Exercise and Diet
4.66
± 1.66
Diet Only
3.81
± 1.30
21 weeks
Group
Value
95% CI
Exercise and Diet
4.53
± 1.46
Diet Only
3.95
± 1.22
C-Reactive Protein (hsCRP)Secondary· Baseline, 21 weeks
hsCRP will be measured from blood serum samples
Baseline
Group
Value
95% CI
Exercise and Diet
8.8
± 12.4
Diet Only
8.8
± 10.2
21 weeks
Group
Value
95% CI
Exercise and Diet
2.6
± 1.3
Diet Only
5.2
± 4.0
Lower Extremity Bone Mineral Density (BMD) - FemurSecondary· Baseline, 21 weeks
The changes in Bone Mineral Density will be measured using DXA scan
Baseline
Group
Value
95% CI
Home-Based Exercise & Diet Group
0.8
± 0.1
Home-Based Diet Alone Group
0.7
± 0.2
21 weeks
Group
Value
95% CI
Home-Based Exercise & Diet Group
0.8
± 0.2
Home-Based Diet Alone Group
0.7
± 0.2
Adverse events — posted to ClinicalTrials.gov
Time frame: 6 months.
Reporting threshold: 5%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
Evaluate and compare the health benefits of an at home exercise program using functional electrical stimulation (FES) for lower extremity exercise with diet versus a diet alone group in adults with spinal cord injury.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Miami
Last refreshed: 22 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03495986.